Facebook Instagram X-twitter Linkedin

Cagrilintide (10mg)

Table of Contents

  • Quickstart Highlights

Cagrilintide (10mg) protocols focus on this long-acting amylin analog studied for its potential to support appetite regulation, reduce caloric intake, and assist in weight management. By mimicking the natural hormone amylin, Cagrilintide may promote satiety and improve metabolic control. This guide outlines a subcutaneous administration approach optimized for the 10 mg vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical dosing range: 0.25–2 mg per week (subcutaneous)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support appetite control and weight management via amylin receptor activation
  • Schedule: Once-weekly subcutaneous injection due to extended half-life
  • Dose Range: 0.25–2 mg per week
  • Dosing Protocol

Suggested approach for the 10 mg vial format.

  • Start: 0.25 mg once weekly to assess tolerance
  • Titration: Gradually increase (e.g., 0.5 mg → 1 mg → up to 2 mg weekly)
  • Target: 1–2 mg once weekly
  • Frequency: Once per week (subcutaneous)
  • Vial Duration: One 10 mg vial lasts approximately 5–40 weeks, depending on dose
  • Timing: Same day each week; can be taken with or without food
  • Mechanism of Action

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It acts on amylin and calcitonin receptors in the brain, particularly in areas involved in appetite regulation.

By activating these pathways, Cagrilintide slows gastric emptying, increases satiety, and reduces food intake. It may also influence glucagon secretion and improve metabolic balance. Its prolonged activity allows for once-weekly dosing, making it a promising candidate in weight management research, especially when combined with other metabolic agents.

  • Potential Benefits & Side Effects

Observations based on preclinical and clinical research.

Potential Benefits:

  • May significantly reduce appetite and caloric intake
  • May support sustained weight loss
  • May improve metabolic markers related to glucose regulation
  • Long-acting profile allows convenient weekly dosing

Possible Side Effects:

  • Nausea (most commonly reported, especially during dose escalation)
  • Reduced appetite leading to low energy in some individuals
  • Injection-site reactions
  • Long-term safety still under investigation; remains an investigational compound